SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - FRA:1SXP - DE000A3ENQ51 - Common Stock
20.25 EUR
+0.15 (+0.75%)
1SXP gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 21 industry peers in the Life Sciences Tools & Services industry. While 1SXP belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. 1SXP is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year 1SXP was profitable.
1SXP had a positive operating cash flow in the past year.
1SXP had positive earnings in each of the past 5 years.
In the past 5 years 1SXP always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 9.61%, 1SXP belongs to the top of the industry, outperforming 95.24% of the companies in the same industry.
The Return On Equity of 1SXP (17.01%) is better than 90.48% of its industry peers.
With an excellent Return On Invested Capital value of 13.93%, 1SXP belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for 1SXP is significantly above the industry average of 7.48%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.01% | ||
| ROIC | 13.93% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
1.3 Margins
1SXP has a better Profit Margin (15.05%) than 80.95% of its industry peers.
1SXP's Profit Margin has been stable in the last couple of years.
The Operating Margin of 1SXP (19.47%) is better than 71.43% of its industry peers.
1SXP's Operating Margin has improved in the last couple of years.
1SXP's Gross Margin of 33.73% is on the low side compared to the rest of the industry. 1SXP is outperformed by 61.90% of its industry peers.
1SXP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.47% | ||
| PM (TTM) | 15.05% | ||
| GM | 33.73% |
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
1SXP has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, 1SXP has about the same amount of shares outstanding.
The debt/assets ratio for 1SXP is higher compared to a year ago.
2.2 Solvency
The Debt to FCF ratio of 1SXP is 1.74, which is an excellent value as it means it would take 1SXP, only 1.74 years of fcf income to pay off all of its debts.
1SXP has a better Debt to FCF ratio (1.74) than 100.00% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that 1SXP is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.09, 1SXP belongs to the top of the industry, outperforming 95.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.74 | ||
| Altman-Z | N/A |
ROIC/WACC1.72
WACC8.12%
2.3 Liquidity
1SXP has a Current Ratio of 1.57. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
1SXP's Current ratio of 1.57 is in line compared to the rest of the industry. 1SXP outperforms 42.86% of its industry peers.
1SXP has a Quick Ratio of 1.17. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
1SXP has a Quick ratio of 1.17. This is in the lower half of the industry: 1SXP underperforms 61.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
1SXP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.00%.
1SXP shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.04% yearly.
1SXP shows a small growth in Revenue. In the last year, the Revenue has grown by 2.86%.
Measured over the past years, 1SXP shows a quite strong growth in Revenue. The Revenue has been growing by 13.84% on average per year.
EPS 1Y (TTM)-3%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-3.23%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
3.2 Future
Based on estimates for the next years, 1SXP will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.71% on average per year.
The Revenue is expected to grow by 7.72% on average over the next years.
EPS Next Y4.98%
EPS Next 2Y10.58%
EPS Next 3Y12.5%
EPS Next 5Y10.71%
Revenue Next Year2.61%
Revenue Next 2Y5.89%
Revenue Next 3Y7.4%
Revenue Next 5Y7.72%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 20.88, the valuation of 1SXP can be described as rather expensive.
76.19% of the companies in the same industry are more expensive than 1SXP, based on the Price/Earnings ratio.
1SXP's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.67.
The Price/Forward Earnings ratio is 16.73, which indicates a correct valuation of 1SXP.
Based on the Price/Forward Earnings ratio, 1SXP is valued cheaply inside the industry as 80.95% of the companies are valued more expensively.
1SXP is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.33, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.88 | ||
| Fwd PE | 16.73 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1SXP indicates a rather cheap valuation: 1SXP is cheaper than 80.95% of the companies listed in the same industry.
66.67% of the companies in the same industry are cheaper than 1SXP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 61.52 | ||
| EV/EBITDA | 11.53 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
1SXP has an outstanding profitability rating, which may justify a higher PE ratio.
1SXP's earnings are expected to grow with 12.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.19
PEG (5Y)N/A
EPS Next 2Y10.58%
EPS Next 3Y12.5%
5. Dividend
5.1 Amount
With a yearly dividend of 0.80%, 1SXP is not a good candidate for dividend investing.
In the last 3 months the price of 1SXP has falen by -22.26%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
1SXP's Dividend Yield is rather good when compared to the industry average which is at 0.69. 1SXP pays more dividend than 80.95% of the companies in the same industry.
With a Dividend Yield of 0.80, 1SXP pays less dividend than the S&P500 average, which is at 2.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.8% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
1SXP pays out 16.41% of its income as dividend. This is a sustainable payout ratio.
DP16.41%
EPS Next 2Y10.58%
EPS Next 3Y12.5%
FRA:1SXP (10/23/2025, 7:00:00 PM)
20.25
+0.15 (+0.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners19.52%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.05B
Revenue(TTM)975.68M
Net Income(TTM)146.87M
Analysts78.95
Price Target30.13 (48.79%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.8% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.41%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.21%
Min EPS beat(2)-1.05%
Max EPS beat(2)5.48%
EPS beat(4)1
Avg EPS beat(4)-5.25%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)4
Avg EPS beat(8)6.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)1.75%
Revenue beat(4)1
Avg Revenue beat(4)-2.21%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.79%
PT rev (3m)-1.16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.9%
EPS NY rev (1m)0.33%
EPS NY rev (3m)0.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.5%
Revenue NY rev (1m)-0.59%
Revenue NY rev (3m)-2.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.88 | ||
| Fwd PE | 16.73 | ||
| P/S | 3.13 | ||
| P/FCF | 61.52 | ||
| P/OCF | 14.98 | ||
| P/B | 3.53 | ||
| P/tB | 3.66 | ||
| EV/EBITDA | 11.53 |
EPS(TTM)0.97
EY4.79%
EPS(NY)1.21
Fwd EY5.98%
FCF(TTM)0.33
FCFY1.63%
OCF(TTM)1.35
OCFY6.67%
SpS6.48
BVpS5.73
TBVpS5.53
PEG (NY)4.19
PEG (5Y)N/A
Graham Number11.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.01% | ||
| ROCE | 17.04% | ||
| ROIC | 13.93% | ||
| ROICexc | 14.46% | ||
| ROICexgc | 14.87% | ||
| OM | 19.47% | ||
| PM (TTM) | 15.05% | ||
| GM | 33.73% | ||
| FCFM | 5.08% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
ROICexc(3y)16.18%
ROICexc(5y)17.77%
ROICexgc(3y)16.78%
ROICexgc(5y)18.78%
ROCE(3y)19.2%
ROCE(5y)20.87%
ROICexgc growth 3Y-8.59%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.46%
ROICexc growth 5YN/A
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.74 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 204.37% | ||
| Cap/Sales | 15.78% | ||
| Interest Coverage | 12.16 | ||
| Cash Conversion | 76.71% | ||
| Profit Quality | 33.75% | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | N/A |
F-Score5
WACC8.12%
ROIC/WACC1.72
Cap/Depr(3y)291.84%
Cap/Depr(5y)279.9%
Cap/Sales(3y)17.77%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.98%
Profit Quality(5y)27.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-3%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-3.23%
EPS Next Y4.98%
EPS Next 2Y10.58%
EPS Next 3Y12.5%
EPS Next 5Y10.71%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
Revenue Next Year2.61%
Revenue Next 2Y5.89%
Revenue Next 3Y7.4%
Revenue Next 5Y7.72%
EBIT growth 1Y12.19%
EBIT growth 3Y18.37%
EBIT growth 5YN/A
EBIT Next Year46.93%
EBIT Next 3Y24.15%
EBIT Next 5Y18.33%
FCF growth 1Y-28.77%
FCF growth 3Y33.55%
FCF growth 5YN/A
OCF growth 1Y-5.41%
OCF growth 3Y19.45%
OCF growth 5YN/A